Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food and Esomeprazole on Alectinib PK
NCT02023125Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2013
- Primary completion
- Mar 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours and Area Under the Curve From Time Zero to Extrapolated Infinite Time at 96 hours. Started Dec 2013; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02023125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023125.